SAMe

By : Bioclinic Naturals™

Indications

• Key factor in several key biological pathways, including methylation reactions, glutathione formation and glutathione-s-transferase activity12
• Complexed with disulfate tosylate, a well tolerated, stable and clinically tested form
• Enteric coating protects SAMe degradation from gastric acid, allowing for significantly
improved intestinal absorption
• 200 mg SAMe per tablet, allows for flexible dose titration
• Sourced from the highest quality Italian Isoactive® SAMe available on the market
• Isoactive SAMe uses a natural fermentation process that yields 40% higher active ingredients over synthetic variations

Ingredients

Each Tablet Contains:
SAMe S-Adenosyl Methionine (from 400 mg SAMe Tosylate Disulfate)...200 mg

Non-medicinal Ingredients:
Microcrystalline cellulose, mannitol, enteric coating (methacrylic acid copolymer, triethyl citrate, glyceryl palmito-stearate, silica, titanium dioxide, medium chain triglycerides, yellow iron oxide), glyceryl behenate, vegetable grade magnesium stearate (lubricant), silica, sodium starch glycolate.

Contains no artificial preservatives or sweeteners and no dairy, soy, wheat or yeast. Sealed for your protection. Do not use if seal is broken. For freshness, store in a cool, dry place.

Description

Features
S-Adenosyl-L-Methionine (SAMe) has several critical physiological functions and is the common thread between three key metabolic pathways. Well-recognized as a unique methyl donor for numerous biological reactions, including DNA methylation, it also links methylation to polyamine synthesis (necessary for cell survival and growth), and trans sulfuration, which is responsible for cysteine production, the rate-limiting factor in glutathione synthesis.1,2 Its unique positioning within these intersecting pathways explain its role as a regulator of redox status, cellular metabolism, proliferation and apoptosis.3,4

Clinically it has proven beneficial for a number of conditions, most notably osteoarthritis, neurodegenerative disease, depression and liver disease.5 For patients with major depressive disorder, SAMe has been shown to be effective not only when compared to standard antidepressants, but also for selective serotonin reuptake inhibitor (SSRI) nonresponders.6,7 SAMe has also shown efficacy for osteoarthritis comparable to NSAIDs, including celecoxib.8,9 Quite importantly, it is likely via increases in cartilage formation, glutathione production, DNA methylation and gene expression which contribute to its efficacy, a stark contrast from pharmaceutical analgesics.10 Research also suggests benefit for neurodegenerative disease, and potentially for improving endothelial function.11

Quantity

30 Enteric Coated Tablets

Dose

Recommended Adult Dose: Take on an empty stomach.

For mood balance: 1–4 tablets 2 times per day or as directed by a health care practitioner.

For osteoarthritic pain: 1–3 tablets 2 times per day or as directed by a health care practitioner. Do not exceed a total of 8 tablets per day. SAMe must be taken for a minimum of 2 weeks, at which time effects should be observed.

Potential side effects/Safety

Contraindications
Consult a health care practitioner if you are taking antidepressant medications. Do not use if you are pregnant or breastfeeding. Do not take at night as SAMe may cause anxiety, restlessness and insomnia. People with bipolar disorder (manic depressive illness) should not use SAMe unless under medical supervision. Possible side effects are: mild gastrointestinal upsets, anxiety, hyperactive muscle movement, insomnia and hypomania. When these side effects occur, they often diminish with time or resolve with lower doses or cessation of use. SAMe could theoretically worsen Parkinson's symptoms, although this has not been observed clinically. Keep out of reach of children.

Deficiency of vitamins B6, B12, and other methyl donors may exacerbate SAMe deficiency. Theoretically may have additive serotonergic effects when used with antidepressants, but this has not been observed clinically, and when used simultaneously, no increase in adverse effects were noted compared to placebo.6

References

"Show references"

"Hide references"

• Park LK, et al. Nutritional influences on epigenetics and age-related disease. Proc Nutr Soc. 2012 Feb;71(1):75-83.
• MartÍnez-LÓpez N, et al. S-adenosylmethionine and proliferation: new pathways, new targets. Biochem Soc Trans. 2008 Oct;36(Pt 5):848-52.
• Finkelstein JD. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine. Clin Chem Lab Med. 2007;45(12):1694-9.
• Lu SC, et al. S-Adenosylmethionine in cell growth, apoptosis and liver cancer. J Gastroenterol Hepatol. 2008 Mar;23 Suppl 1:S73-7.
• Bottiglieri T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside-molecular basis of a pleiotrophic molecule. Am J Clin Nutr. 2002 Nov;76(5):1151S-7S.
• Papakostas GI, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010 Aug;167(8):942-8.
• Williams AL, et al. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clin Invest Med. 2005 Jun;28(3):132-9.
• Kim J, et al. Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients. Clin Ther. 2009 Dec;31(12):2860-72.
• Najm WI, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. BMC Musculoskelet Disord. 2004 Feb 26;5:6.
• Hosea Blewett HJ. Exploring the mechanisms behind S-adenosylmethionine (SAMe) in the treatment of osteoarthritis. Crit Rev Food Sci Nutr. 2008 May;48(5):458-63.
• Shea TB, et al. S-adenosyl methionine: a natural therapeutic agent effective against multiple hallmarks and risk factors associated with Alzheimer's disease. J Alzheimers Dis. 2008 Feb;13(1):67-70.
• Tchantchou F, et al. S-adenosylmethionine mediates glutathione efficacy by increasing glutathione S-transferase activity: implications for S-adenosyl methionine as a neuroprotective dietary supplement. J Alzheimers Dis. 2008 Jul;14(3):323

Disclaimer: This content is subject to change. The information is intended to inform and educate; it does not replace the medical evaluation, advice, diagnosis or treatment by a healthcare professional. www.healthydigestionclinic.com © 2015 NDAssist Inc. and/or its affiliates. All rights reserved.